Yahoo Malaysia Web Search

Sign In

Search results

  1. www.biopharmadive.com › news › ultragenyx-mereo-bone-studyUltragenyx, Mereo drug reduces fractures in bone disorder study

    Jun 12, 2024 · Ultragenyx, Mereo drug reduces fractures in bone disorder study. New data show the experimental treatment’s effect on fractures and bone density held up over time, boosting the drug’s prospects ahead of a Phase 3 readout.

  2. finance.yahoo.com › news › ultragenyx-mereo-biopharma-announceUltragenyx and Mereo BioPharma Announce New Phase 2 Data from...

    Jun 11, 2024 · The partnership with Ultragenyx includes potential additional milestone payments of up to $245 million and royalties to Mereo on commercial sales in Ultragenyx territories.

  3. Videos

    View all

  4. www.fiercebiotech.com › biotech › ultragenyx-wins-surrogateUltragenyx gets green light to seek FDA approval of gene therapy

    Jun 13, 2024 · With the FDA agreeing a biomarker is a reasonable surrogate endpoint, Ultragenyx is preparing to file for approval of its Sanfilippo gene therapy.

  5. www.fiercebiotech.com › biotech › ultragenyx-mereos-brittleUltragenyx, Mereo's brittle bone drug sustains fracture rate cut

    Jun 12, 2024 · Ultragenyx and Mereo BioPharma have broken off another piece of brittle bone data, linking their drug candidate to sustained reductions in fracture rates in a midphase clinical trial.

  6. ir.ultragenyx.com › news-releases › news-release-detailsUltragenyx Announces Plans to File for Accelerated Approval of...

    Jun 12, 2024 · Agreement reached with FDA that cerebral spinal fluid (CSF) heparan sulfate (HS) can be used as a reasonable surrogate endpoint for accelerated approval. Data from existing clinical studies appear sufficient for a biologics license application (BLA) submission.

  7. www.globenewswire.com › news-release › 2024/06/12Ultragenyx Announces Proposed Public Offering of Common -...

    Jun 12, 2024 · About Ultragenyx. Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultrarare genetic diseases.

  8. Images

    • Ultragenyx Pharmaceutical Inc. | $RARE Stock | Shares Rise Up On ...
    • Technical Analysis of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE ...
    • About MPS VII - MEPSEVII HCP

    View all

  9. www.nasdaq.com › articles › ultragenyx-rare-seek-acceleratedUltragenyx (RARE) to Seek Accelerated Nod for Rare Disease Drug

    Jun 13, 2024 · Ultragenyx Pharmaceutical Inc. RARE announced that it is planning to seek accelerated approval for its AAV gene therapy candidate UX111, which is being developed for the treatment of Sanfilippo...